Previous 10 | Next 10 |
HIGH POINT, N.C., Nov. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that ...
CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19 PR Newswire WESTON, Fla. a...
Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer PR Newswire Initiation of Clinical Study at Allegheny Health Network Seeks to Provide Treatment Options t...
2023-09-22 05:22:36 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some investors believe that the market is always correct and that stock prices always accurately reflect reality. As a result, they will rarely if ever buy stocks that are tumbling and that are...
CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA PR Newswire Initiation of Clinical Study at Lenox Hill Hospital Seeks to Provide New Option for Treatmen...
2023-08-11 16:43:34 ET vTv Therapeutics press release ( NASDAQ: VTVT ): Q2 GAAP EPS of -$0.07. The Company’s cash position as of June 30, 2023, was $12.6 million compared to $12.1 million as of December 31, 2022. Shares +1.53% . For further d...
HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial...
Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer PR Newswire Cantex's once daily, orally administered, azeliragon inhibits interactions of the receptor ...
2023-08-06 12:00:54 ET Only a tiny fraction of adults in the U.S. are using prescription weight loss drugs, while many more are looking forward to taking them if the meds are proven to be safe and effective, a new survey by the healthcare policy organization Kaiser Family Foundation shows. ...
HIGH POINT, N.C., June 16, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin ( TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), announced today that...
News, Short Squeeze, Breakout and More Instantly...
vTv Therapeutics Inc. Company Name:
VTVT Stock Symbol:
NASDAQ Market:
vTv Therapeutics Inc. Website:
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has pla...
2024-06-26 16:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D Cadisegliatin has been dosed in over ...